Stock Events

Stock Events

Arch Biopartners 

$0.41
3
+$0.08+25.41% Wednesday 19:22

Statistics

Day High
0.42
Day Low
0.36
52W High
1.42
52W Low
0.33
Volume
37,200
Avg. Volume
32,334
Mkt Cap
27.28M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

2JunExpected
Q1 2024
Q2 2024
Q4 2024
Q1 2025
Q2 2025
Q4 2025
Next
-0.02
-0.01
-0.01
-0
Expected EPS
N/A
Actual EPS
N/A

Financials

-564.15%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
393,719.08Revenue
-2.22MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ACHFF. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals is a competitor because it also focuses on developing treatments for serious diseases, similar to Arch Biopartners' focus on critical diseases including bacterial infections and inflammation.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals competes in the biopharmaceutical space, particularly in developing monoclonal antibodies, a field where Arch Biopartners is also active.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences is a competitor due to its strong presence in the antiviral and anti-inflammatory drug market, areas that overlap with Arch Biopartners' research interests.
AMGEN
AMGN
Mkt Cap160.66B
Amgen competes with Arch Biopartners in the biotech space, focusing on innovative therapeutics, including treatments for inflammatory diseases.
Biogen
BIIB
Mkt Cap22.63B
Biogen is a competitor because of its focus on developing therapies for neurological and neurodegenerative diseases, competing with Arch Biopartners' interest in novel drug candidates.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie is a competitor as it has a broad portfolio of biopharmaceuticals, including anti-inflammatory and antiviral drugs, overlapping with Arch Biopartners' areas of interest.
Pfizer
PFE
Mkt Cap140.15B
Pfizer competes with Arch Biopartners through its extensive research and development in various therapeutic areas, including anti-infectives.
Merck
MRK
Mkt Cap214.76B
Merck is a competitor because of its global healthcare presence and focus on pharmaceuticals that address serious health issues, similar to Arch Biopartners' mission.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca is a competitor due to its wide range of therapeutic products, including treatments for infections and chronic diseases, areas where Arch Biopartners is also active.
Novartis
NVS
Mkt Cap237.61B
Novartis competes with Arch Biopartners in the global healthcare market, focusing on innovative medicines, including those for infectious and inflammatory diseases.

About

Arch Biopartners Inc., together with its subsidiaries, engages in the development of novel drugs for acute kidney injury and organ damage in Canada. It focuses on developing its lead drug candidate LSALT Peptide, which is in Phase 2 trials to treat inflammation related acute kidney injury experienced by patients undergoing on-pump (bypass) cardiac surgery; and cilastatin to prevent toxin related acute kidney injury via dipeptidase-1. The company also develops AB569 for treating antibiotic-resistant bacterial infections and as a topical treatment for wounds; and Borg, a peptide-solid surface interface, which are binding of proprietary peptides to solid metal and plastic surfaces to inhibit biofilm formation and to reduce corrosion. Arch Biopartners Inc. is based in Toronto, Canada.
Show more...
CEO
Mr. Richard Gabriel Muruve
Country
CA
ISIN
CA03938C1041

Listings

V
CA
ARCH.V
OTC Link
US
ACHFF

0 Comments

Share your thoughts

FAQ

What is Arch Biopartners stock price today?▼
The current price of ACHFF is $0.41 USD — it has increased by +25.41% in the past 24 hours. Watch Arch Biopartners stock price performance more closely on the chart.
What is Arch Biopartners stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Arch Biopartners stocks are traded under the ticker ACHFF.
Is Arch Biopartners stock price growing?▼
ACHFF stock has risen by +6.61% compared to the previous week, the month change is a -31.23% fall, over the last year Arch Biopartners has showed a -67.25% decrease.
What is Arch Biopartners market cap?▼
Today Arch Biopartners has the market capitalization of 27.28M
When is the next Arch Biopartners earnings date?▼
Arch Biopartners is going to release the next earnings report on June 02, 2026.
What is Arch Biopartners revenue for the last year?▼
Arch Biopartners revenue for the last year amounts to 393,719.08 USD.
What is Arch Biopartners net income for the last year?▼
ACHFF net income for the last year is -2.22M USD.
In which sector is Arch Biopartners located?▼
Arch Biopartners operates in the Health Care sector.
When did Arch Biopartners complete a stock split?▼
Arch Biopartners has not had any recent stock splits.
Where is Arch Biopartners headquartered?▼
Arch Biopartners is headquartered in Toronto, CA.